Novo Nordisk (NVO) Stock Target Set at $47 by Goldman Sachs
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowGoldman Sachs has maintained its Neutral rating and $47 price target on Novo Nordisk (NVO) after meeting with the management at the 47th Annual Global Healthcare Conference on June 9. This target represents a 7% upside from the closing price of 287.25 Danish kroner on June 12, which was up 1.66% for the day. Earlier this year, Novo shares dropped to a 52-week low near $37 following disappointing trial results for its drug CagriSema. Additionally, it held a 39% market share in the U.S. obesity and diabetes GLP-1 market, compared to Eli Lilly’s 60%.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About The Goldman Sachs Group (GS)
Goldman Sachs is a leading global investment bank specializing in advisory, trading, and asset and wealth management.
The Financials sector covers banks, insurers and capital-markets firms at the center of the economy.
Earlier GS news
- CD Rates Today: Lock in 4% APY on Goldman Sachs Offers
- Goldman Sees AI Capex Boost for S&P 500's Return on Equity
- Boston Scientific (BSX) Price Target Cut to $64 by Truist
- Best CD Rates June 2026: Top Account Offers 4% APY Today
- Goldman (GS) and JPMorgan (JPM) Adjust Office Policies for World Cup
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
